Acute Myeloid Leukemia Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for acute myeloid leukemia disease. 86 active patents protecting 7 drugs from 7+ originators. First major cliff: 2030. Daily refresh.

7
Approved drugs
86
Active US patents
58/100
Avg vulnerability
$2.9B
Annual revenue covered

Originators in Acute Myeloid Leukemia Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AbbVie 30 patents Nippon Shinyaku Co., Ltd. 14 patents Rigel Pharms 14 patents Pfizer 10 patents Servier 10 patents Bristol-Myers Squibb 6 patents Novartis 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating acute myeloid leukemia disease. Each bar = one year. Y-axis scaled to peak year (22 patents).

5
27
4
28
8
29
7
30
6
31
9
32
22
33
8
35
7
36
10
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Venclexta
venetoclax
 AbbVie 30 47 $2.6B 2030-05-26
Rezlidhia
OLUTASIDENIB
 Rigel Pharms 14 55 — 2035-09-18
Cytarabine
Cytarabine
 Nippon Shinyaku Co., Ltd. 14 51 — 2027-01-23
Daurismo
Glasdegib Maleate
 Pfizer 10 43 $150M 2028-06-29
Tibsovo
IVOSIDENIB
 Servier 10 62 — 2030-06-21
Vidaza
azacitidine
 Bristol-Myers Squibb 6 73 — 2029-05-14
Rydapt
MIDOSTAURIN
 Novartis 2 72 $200M 2028-10-09

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12053482 Vidaza method of use 88 2029-05-14
12053482 Vidaza method of use 88 2029-05-14
7973031 Rydapt method of use 75 2028-10-09
12275715 Rezlidhia method of use 75 2035-09-18
11891372 Daurismo method of use 75 2036-04-13
11891372 Daurismo method of use 75 2036-04-13
11667673 Tibsovo method of use 70 2033-01-18
11413282 Venclexta method of use 70 2033-09-06
11590128 Venclexta method of use 70 2033-09-06
11590128 Venclexta method of use 70 2033-09-06

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10414748 Daurismo composition of matter 4 2036-04-13
10414748 Daurismo composition of matter 4 2036-04-13
8722657 Venclexta composition of matter 10 2032-01-29
8722657 Venclexta composition of matter 10 2032-01-29
8722657 Venclexta composition of matter 10 2032-01-29
10730873 Venclexta composition of matter 10 2031-11-21
10730873 Venclexta composition of matter 10 2031-11-21
10730873 Venclexta composition of matter 10 2031-11-21
8546399 Venclexta composition of matter 10 2031-06-27
8546399 Venclexta composition of matter 10 2031-06-27

Related